A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State

NCT00744679 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Natalizumab

Sponsor

Biogen

Collaborators

[object Object]